BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...$136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments...
BioCentury | Sep 16, 2019
Financial News

Sept. 16 Financial Quick Takes: Karyopharm, Mission Bay, Autolus, BenevolentAI, Edigene

...team. LPs include Astellas Venture Management, Banyan Pacific Capital, Eli Lilly and Co. (NYSE:LLY), Mayfield, UC Investments...
Items per page:
1 - 2 of 2
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...$136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments...
BioCentury | Sep 16, 2019
Financial News

Sept. 16 Financial Quick Takes: Karyopharm, Mission Bay, Autolus, BenevolentAI, Edigene

...team. LPs include Astellas Venture Management, Banyan Pacific Capital, Eli Lilly and Co. (NYSE:LLY), Mayfield, UC Investments...
Items per page:
1 - 2 of 2